New cancer drug CT7439 enters human testing

NCT ID NCT06600789

Recruiting now Disease control Sponsor: Carrick Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Nov 03, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This early-phase study tests a new drug called CT7439, alone or with other cancer treatments, in about 50 adults with solid tumors that have not responded to standard therapy. The main goal is to check safety and find the best dose. Researchers will also watch for any tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research site 01
RECRUITING

San Antonio, Texas, 78229, United States
Research site 02
RECRUITING

Fairfax, Virginia, 22031, United States
Research site 03
RECRUITING

Dallas, Texas, 75230-2571, United States
Research site 04
RECRUITING

Oxford, OX37LE, United Kingdom
Research site 05
RECRUITING

Manchester, M20 4GJ, United Kingdom
Research site 06
RECRUITING

Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.

SOLID MALIGNANCIES